Ján Kliment, Vladimír Malec, Jozef Mardiak, Michal Mego
In recent years, treatment of metastatic castration-resistant prostate cancer (mRRKP) has significantly changed. The
new drugs, abiraterone, enzalutamide, sipuleucel, radium-223, docetaxel, cabazitaxel, prolong the survival of patients
with improved quality of life. The use of new drugs with a different mechanism of action in the heterogeneity of prostate
cancer leads to the need to focus on choosing the optimal treatment for an individual patient. Questions regarding
the sequence using various drugs or combinations remain for lack of evidence discussed and require further validation
in clinical trials. The Delphi Panel of Experts addresses some of the mKRKP’s treatment issues in Slovakia.